BrightGene Bio-Medical Technology Co., Ltd. (SHA:688166)
China flag China · Delayed Price · Currency is CNY
27.03
-0.86 (-3.08%)
At close: Nov 17, 2026

SHA:688166 Income Statement

Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Revenue
1,3091,1901,2481,1611,0131,050
Other Revenue
34.1434.1434.2718.344.042.25
1,3431,2241,2831,1801,0171,052
Revenue Growth
13.81%-4.59%8.73%15.94%-3.33%34.00%
Cost of Revenue
632.75615.41560.51542.9390.95470.07
Gross Profit
710.22608.23722.04636.61626.38582.34
Selling, General & Admin
225.86232.53210.87180.46184.98145.56
Research & Development
329.83304.95297.45248.59207.02173.29
Other Operating Expenses
10.45-0.491.39-1.595.224.22
Operating Expenses
604.35556.67521.27428.37395333.18
Operating Income
105.8751.56200.76208.24231.38249.16
Interest Expense
-72.15-62.96-52.44-44.42-23.71-9.7
Interest & Investment Income
17.445.5510.9617.996.210.14
Currency Exchange Gain (Loss)
6.096.091.922.612.994.63
Other Non Operating Income (Expenses)
-20.97-2.07-2.14-1.88-2.17-1.77
EBT Excluding Unusual Items
36.29-1.83159.07182.54224.68252.46
Impairment of Goodwill
-3.12-3.12-4.38---
Gain (Loss) on Sale of Investments
28.58-5.54-17.33-15.26-3.390.79
Gain (Loss) on Sale of Assets
-5.13-0.5-0.15-0.25-0.01-0.26
Asset Writedown
-0.28-----
Other Unusual Items
24.8924.8919.9921.7420.934.47
Pretax Income
81.2313.91157.2188.77242.21257.46
Income Tax Expense
-23.13-23.0515.9415.3530.7819.9
Earnings From Continuing Operations
104.3736.95141.26173.42211.43237.56
Minority Interest in Earnings
-2.0917.5647.929.0428.26.39
Net Income
102.2854.51189.17202.47239.62243.95
Net Income to Common
102.2854.51189.17202.47239.62243.95
Net Income Growth
64.76%-71.18%-6.57%-15.51%-1.77%43.60%
Shares Outstanding (Basic)
425419420422413407
Shares Outstanding (Diluted)
425419420422413407
Shares Change
1.58%-0.24%-0.34%2.10%1.61%-1.87%
EPS (Basic)
0.240.130.450.480.580.60
EPS (Diluted)
0.240.130.450.480.580.60
EPS Growth
62.19%-71.11%-6.25%-17.24%-3.33%46.34%

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
152.24-128.22-11.64-209-415.47-733.59
Free Cash Flow Per Share
0.36-0.31-0.03-0.49-1.01-1.80
Dividend Per Share
0.0160.0160.0960.0960.1140.120
Dividend Growth
-83.33%-83.33%0%-15.79%-5.00%42.86%
Gross Margin
52.88%49.71%56.30%53.97%61.57%55.33%
Operating Margin
7.88%4.21%15.65%17.66%22.74%23.67%
Profit Margin
7.62%4.46%14.75%17.16%23.55%23.18%
Free Cash Flow Margin
11.34%-10.48%-0.91%-17.72%-40.84%-69.71%
EBITDA
284.16195.13298.05275.07271.03283.34
EBITDA Margin
21.16%15.95%23.24%23.32%26.64%26.92%
D&A For EBITDA
178.28143.5797.2866.8339.6534.18
EBIT
105.8751.56200.76208.24231.38249.16
EBIT Margin
7.88%4.21%15.65%17.66%22.74%23.67%
Effective Tax Rate
--10.14%8.13%12.71%7.73%
Revenue as Reported
1,3431,2241,2831,1801,0171,052
Advertising Expenses
-1.692.28-0.521.01